Disclosure Plus

Genexine, Inc.: With the Prospects for Its Bio-PROTAC Technology Transfer Still Uncertain… Is It Playing the ‘AI New Business’ Card This Time?

KIM SAE-MI
2026-11-21 07:42:03
[Edaily Reporter KIM SAE-MI ] Genexine, Inc.(095700), which positioned bioPROTAC as a new growth engine following its 2024 merger with EPD Biotherapeutics (EPD Bio), is now turning its attention to a new artificial intelligence (AI) business. However, with delays in the development and commercialization of its existing drug candidates and a tight financial situation, it remains to be seen how effective this foray into a new business will be.

Genexine, Inc. Magok headquarters (Photo:KIM SAE-MI reporter)

Data Center Business Put on Hold After Just One Month… Shift to Medical AI
According to the biotech industry on the 17th, Genexine, Inc. plans to hold an extraordinary general meeting of shareholders at its Magok headquarters in Gangseo-gu, Seoul, on the 20th to push for amendments to its articles of incorporation. The company intends to add “information and communications services” and “manufacturing and services related to AI medical robotics and mobility” to its existing business objectives.

Genexine, Inc. deleted all data center-related items via a corrected disclosure on the 2nd. (Source: Financial Supervisory Service Electronic Disclosure System)

The direction of the new business was revised within a month. In its initial disclosure on the 6th of last month, Genexine, Inc. had intended to add a total of 10 items, including eight data center-related business purposes such as medical and biotech data centers, as well as cloud and AI data centers. However, in a corrected disclosure on the 2nd, the company removed all data center-related items, leaving only two. The plan is to expand its business scope with a focus on medical AI rather than immediately pursuing the data center business.

A Genexine, Inc. official stated, “We determined that data centers involve a significant amount of hardware, which does not align with Genexine, Inc. at this time,” adding, “We intend to first apply AI to areas necessary for new drug development.” Regarding the reason for adding robotics and mobility businesses, the official replied, “For now, we plan to focus on medical AI,” and noted, “We also plan to continue expanding our business scope if possible.”

Bioprotac Clinical Trials Delayed by Over a Year… Technology Transfer Also Uncertain
The development schedule for BioProTac, which the company had previously touted as a new growth engine, is falling behind the original plan. Genexine, Inc. secured the BioProTac platform by merging with EPD Bio in October 2024. The key candidate compound, “GX-BP1,” is being developed to degrade the SOX2 transcription factor, which is associated with drug resistance in lung cancer.

The target date for submitting the Investigational New Drug (IND) application for GX-BP1—originally set for “February 2026” at the end of 2024—was revised to “mid-2027” in April of this year. This represents a delay of approximately 16 months compared to the original plan. In a phone call with Edaily on the 13th, CEO Choi projected that GX-BP1 would enter clinical trials in the second half of next year. This represents a delay of more than one year and four months compared to the original target.

The delay in the development schedule was influenced by preparations for toxicity testing and negotiations regarding joint development partnerships. CEO Choi explained, “It took time to decide whether to proceed with the monkey toxicity study, and preparatory processes, such as the production of test samples, were also necessary.”

Genexine, Inc. maintains that the clinical schedule is being delayed because the company must first confirm the interest of global pharmaceutical companies in technology transfer based on the results of the monkey toxicity tests at the end of the year before deciding whether to proceed with its own clinical trials.

Genexine, Inc. is currently discussing joint development plans for GX-BP1 with a lipid nanoparticle (LNP) developer. Choi Jae-hyun, CEO of Genexine, Inc., said, “We are discussing a joint development partnership with the LNP developer, so the timing of our entry into clinical trials may vary depending on the outcome.”

Genexine, Inc.’s preferred scenario is to license the technology to a global pharmaceutical company before proceeding with its own clinical trials. CEO Choi emphasized, “The raw data from the monkey toxicity test results will be available by the end of this year,” adding, “There are several companies awaiting these results, so we plan to monitor their feedback for about three months starting early next year.” He explained, “Our most desired scenario is to transfer the technology to a global pharmaceutical company without entering clinical trials,” but added, “If the companies considering the technology transfer require a human proof-of-concept (POC), we will have to proceed with clinical trials.”

The technology transfer plan has also fallen behind the initial target. At a shareholder meeting in November 2024, CEO Choi set a goal of generating revenue through a global technology transfer in the first half of 2026. Last October, he announced plans to sign a contract by June of this year, or by the end of the year at the latest.

However, it is unlikely that a technology transfer agreement will be finalized by the end of this year. When asked about the possibility of a technology transfer agreement in the first half of next year, a representative of Genexine, Inc. replied, “It is quite difficult to specify a timeline.” Nevertheless, he added, “We are currently attending the BIO-Europe event in Germany and holding meetings with various companies,” noting, “The response has been positive across the board, so we are looking at this optimistically.”

Recurring Delays in New Drug Development Timelines… Is There Room for Investment in New AI Ventures?
This is not the first time Genexine, Inc. has had to revise
its schedule
. Genexine, Inc.’s existing drug candidates are also struggling to gain momentum toward commercialization.

For the growth hormone therapy “GX-H9,” Chinese partner TJ Bio completed Phase 3 clinical trials and applied for marketing authorization in December 2024 but voluntarily withdrew the application. Subsequently, in August of this year, it resubmitted the application for the pen formulation. The GLP-1 class diabetes and obesity treatment “GX-G6” is also in the process of obtaining marketing authorization in China, following the completion of Phase 3 clinical trials for two indications by its Chinese partner. Since it has not yet received approval in China, the commercialization timeline remains undetermined.

The anemia treatment “Efesa (GX-E4)” received marketing authorization in Indonesia in October 2023 and was launched the following April; however, in South Korea, the company is preparing to resubmit its marketing authorization application—originally filed in November 2024—after addressing the requested revisions. Genexine, Inc. announced in June that it would pursue a resubmission within a few months following the rejection of its marketing authorization application, but has yet to specify a concrete timeline for the resubmission.

With the commercialization of its existing pipeline facing delays, another key issue is whether the company has the financial capacity to invest in new business ventures. As of the end of the third quarter of this year, Genexine, Inc.’s cash and cash equivalents (including short-term financial instruments) totaled 15.3 billion won. Cumulative revenue for the first three quarters was 5.5 billion won, while the operating loss reached 26.6 billion won. Last October, Genexine, Inc. stated that its annual cash burn rate was around 32 billion won and that it would prioritize the sale of real estate and investment assets if additional funds were needed.

Recent attempts to raise funds have also hit a snag. On the 16th of last month, Genexine, Inc. decided to conduct a third-party private placement worth 3 billion won with Korea Quantum iA, Inc. At the time, Genexine, Inc. explained that the investment was related to its data center business. However, since the investment funds were not received by the payment deadline of the 26th, the company withdrew the capital increase just ten days later. Subsequently, Genexine, Inc. removed eight business objectives related to data centers from its proposed amendments to the articles of incorporation.

This amendment to the articles of incorporation is interpreted as a preliminary move aimed at pursuing new business ventures through external investment. CEO Choi stated, “Although nothing has been decided in concrete terms yet, we have received proposals for new business opportunities contingent on external investment,” adding, “Since it is difficult to pursue the AI data center business with the company’s current financial resources, we are in the stage of making preliminary preparations to pursue new businesses with external funding.”

Economy

Corporation

IT·Science

Economy

Sell-off After Sell-off… All Eyes on Inflation Indicators [Lee Jeong Hun’s Coin Weekly Review]

The price of Bitcoin plummeted to around $55,000 at one point during the week. This marked its lowest level in over two years. Having previously recorded six consecutive weeks of decline—a feat that h…
2026-11-22 10:28:20

Corporation

"Beyond the Domestic Home Shopping Market to Vietnam": GS Retail Sees Success in Export Consultations with Small and Medium-Sized Enterprises

GS Retail(007070)has supported domestic small and medium-sized partner companies in Vietnam in expanding their overseas sales channels, resulting in export consultation deals totaling approximately $1…
2026-11-22 18:23:06

IT·Science

“One Game Rakes in 5 Trillion Won in a Single Day”… UK Networks Set New Records Amid GTA 6 Craze

A single video game generated $3.79 billion (approximately 5 trillion won) in sales worldwide on its first day of release. Pre-orders alone totaled 32.5 million copies before the official launch. As u…
2026-11-22 16:57:26